Literature DB >> 1706591

Synthetic peptides corresponding to the F protein of RSV stimulate murine B and T cells but fail to confer protection.

M Trudel1, E J Stott, G Taylor, D Oth, G Mercier, F Nadon, C Séguin, C Simard, M Lacroix.   

Abstract

We have previously located a major neutralization site of the fusion protein of respiratory syncytial virus (RSV) in the polypeptide region extending from amino acids Ile221 to Glu232. In this report, 8 peptides corresponding to the six major hydrophilic regions of the F1 subunit were selected to analyse their immunogenic and protective capacities as well as their ability to block the high neutralization activities of 4 monoclonal antibodies (MAbs). Only 5 of the 8 peptides tested induced specific antibodies while all induced an in vitro interleukin-2 response of splenocytes from immunized mice. Peptide 3 (Ile221-Phe237) was able to elicit neutralizing antibodies, confirming our previous hypothesis concerning the location of a neutralization site. However, immunization with the latter did not induce significant reduction of virus in lungs of BALB/c mice upon challenge, probably due to an inadequate level of circulating neutralizing antibodies. Interestingly, peptides 2 (Asn216-Glu232), 3 (Ile221-Phe237), and 5 (Ser275-Ile288) blocked in vitro neutralization by four different F1 specific MAbs. A hypothesis is proposed to explain these results.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1706591     DOI: 10.1007/bf01310492

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  27 in total

1.  Identification of epitopes on respiratory syncytial virus proteins by competitive binding immunoassay.

Authors:  L J Anderson; J C Hierholzer; Y O Stone; C Tsou; B F Fernie
Journal:  J Clin Microbiol       Date:  1986-03       Impact factor: 5.948

2.  Preparation and characterization of monoclonal antibodies directed against five structural components of human respiratory syncytial virus subgroup B.

Authors:  C Orvell; E Norrby; M A Mufson
Journal:  J Gen Virol       Date:  1987-12       Impact factor: 3.891

3.  Experimental polyvalent ISCOMs subunit vaccine induces antibodies that neutralize human and bovine respiratory syncytial virus.

Authors:  M Trudel; F Nadon; C Séguin; C Simard; G Lussier
Journal:  Vaccine       Date:  1989-02       Impact factor: 3.641

4.  Identification of a linear epitope on the fusion glycoprotein of respiratory syncytial virus.

Authors:  G E Scopes; P J Watt; P R Lambden
Journal:  J Gen Virol       Date:  1990-01       Impact factor: 3.891

Review 5.  Respiratory syncytial virus. Brief review.

Authors:  E J Stott; G Taylor
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

6.  Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.

Authors:  R A Olmsted; N Elango; G A Prince; B R Murphy; P R Johnson; B Moss; R M Chanock; P L Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

7.  The characterization and uses of monoclonal antibodies to respiratory syncytial virus.

Authors:  E J Stott; M H Bew; G Taylor; J Jebbett; A P Collins
Journal:  Dev Biol Stand       Date:  1984

8.  The development of monoclonal antibodies to respiratory syncytial virus and their use in diagnosis by indirect immunofluorescence.

Authors:  E G Routledge; J McQuillin; A C Samson; G L Toms
Journal:  J Med Virol       Date:  1985-03       Impact factor: 2.327

9.  Morphogenesis and structure of caprine respiratory syncytial virus.

Authors:  H D Lehmkuhl; M H Smith; R C Cutlip
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

10.  Monoclonal antibodies protect against respiratory syncytial virus infection in mice.

Authors:  G Taylor; E J Stott; M Bew; B F Fernie; P J Cote; A P Collins; M Hughes; J Jebbett
Journal:  Immunology       Date:  1984-05       Impact factor: 7.397

View more
  7 in total

1.  A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo.

Authors:  D Chargelegue; O E Obeid; S C Hsu; M D Shaw; A N Denbury; G Taylor; M W Steward
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

2.  Evolution of bovine respiratory syncytial virus.

Authors:  J F Valarcher; F Schelcher; H Bourhy
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines.

Authors:  H Sakurai; R A Williamson; J E Crowe; J A Beeler; P Poignard; R B Bastidas; R M Chanock; D R Burton
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

Review 4.  Respiratory syncytial virus vaccine development.

Authors:  Yoshihiko Murata
Journal:  Clin Lab Med       Date:  2009-12       Impact factor: 1.935

Review 5.  Respiratory syncytial virus vaccines.

Authors:  R A Dudas; R A Karron
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

Review 6.  Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: The antigen scale.

Authors:  Jody D Berry
Journal:  Vet J       Date:  2005-09       Impact factor: 2.688

7.  Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice.

Authors:  Gertrud U Rey; Congrong Miao; Hayat Caidi; Suvang U Trivedi; Jennifer L Harcourt; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.